In a momentous move for precision medicine, the FDA has granted accelerated approval to Loxo Oncology Inc. and Bayer AG's cancer treatment Vitrakvi (larotrectinib) based on a common biomarker rather than the location in the body where the tumor originated.
Vitrakvi has got the thumbs-up for the treatment of both adult and children with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and have no satisfactory alternative treatments or have progressed following therapy